Compounded Semaglutide Legal Status 2026: What the FDA Actually Says

For roughly three years, compounded semaglutide reached patients at scale because the FDA listed semaglutide injection as being in shortage, which suspended the usual limit on compounding copies of an approved drug. That era is over. What remains is the older, narrower pathway that section 503A always permitted. This article lays out the statute, the dates, the FDA's stated positions, and the practical test for whether a given seller is operating inside the rules.

The Legal Framework for Compounding

Pharmacy compounding is governed by the Federal Food, Drug, and Cosmetic Act as amended by the Drug Quality and Security Act of 2013. Two sections define the lawful pathways, and the difference between them decides most questions about compounded GLP-1s.

Section 503A: patient-specific compounding pharmacies

A section 503A pharmacy compounds a preparation for an identified individual patient pursuant to a valid prescription. It is licensed and inspected by its state board of pharmacy, must follow applicable United States Pharmacopeia standards (USP Chapter 797 for sterile injectables), and may only use bulk drug substances that meet the statute's sourcing requirements. Section 503A preparations are exempt from FDA new-drug approval, which is exactly why they are not FDA-approved.

Section 503B: outsourcing facilities

A section 503B outsourcing facility registers with the FDA, is inspected against current Good Manufacturing Practice, and may compound batches without patient-specific prescriptions for hospitals and clinics to keep as office stock. Both sections carry the same restriction that governs this whole subject: a compounder may not regularly produce what is essentially a copy of a commercially available FDA-approved drug. While a drug sits on the FDA's shortage list it is not considered commercially available, and that is the door the shortage opened.

The Shortage Timeline, With the FDA's Dates

The FDA's shortage decisions were not reversed and then reinstated; both resolutions stood. What the agency did do was give compounders time to wind down, and it said explicitly that it did not intend to take action against a 503A pharmacy during that period for compounding a drug that was essentially a copy of the approved product. That grace period is the source of much of the confusion that followed.

What the FDA Actually Says

The FDA's published positions, drawn from its compounding-policy statement issued when GLP-1 supply stabilized and from its standing page on unapproved GLP-1 drugs, come down to five points.

• Compounding has a lawful role, one patient at a time. Section 503A exists for situations where an approved product does not meet an individual patient's need; the prescriber's documented determination of a significant difference is the legal hinge.
• Compounded semaglutide is not FDA-approved. It has not been reviewed for safety, effectiveness, or quality the way Wegovy and Ozempic were, and the FDA says so plainly.
• Salt forms are not the approved active ingredient. The FDA has stated that semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide base in the approved drugs, and that it is not aware of a basis for compounding with those salts under sections 503A or 503B. A seller advertising semaglutide sodium is a red flag, not a loophole.
• Dosing errors have caused harm. The FDA has warned about hospitalizations from compounded semaglutide dosing errors, most involving confusion between units, milliliters, and milligrams when drawing up from a vial. Our dosing-error guide covers how to avoid them.
• Illegal marketing draws warning letters. In 2026 the FDA warned dozens of telehealth companies about unlawful marketing of compounded GLP-1s, including claims that compounded products are FDA-approved or equivalent to the brands, and sales framed as research peptides.

The Salt-Form Rule, Explained

Wegovy and Ozempic contain semaglutide base. Some compounders have used semaglutide sodium or semaglutide acetate, salt forms that are easier to source but are not the active ingredient in any approved drug. The FDA's position is that a salt is a different active ingredient, so a preparation made from it does not qualify for the compounding exemptions in either section 503A or 503B. Practically, that means a lawful compounded product is made from semaglutide base sourced from an FDA-registered bulk-ingredient supplier, and the pharmacy should be able to say so.

State-by-State Variations

Because 503A pharmacies are licensed at the state level, the details vary. Some states require additional disclosures that a compounded medication is not FDA-approved, some have tightened sterile-compounding inspections, and licensing requirements differ for pharmacies that ship into a state from outside it. A pharmacy must be licensed in the state where the patient receives the medication. Every state board offers a free public license lookup; our verification walkthrough shows the check step by step.

What This Means for Patients

If your current provider's pharmacy stops operating, the prescription is yours; our continuity guide explains how to move it without a gap in treatment.

Looking Ahead

• Enforcement, not new law. The 2026 landscape is shaped by how the FDA and state boards enforce the existing copies restrictions, and by warning letters to sellers who market compounded products unlawfully.
• Brand direct-to-consumer channels. Novo Nordisk and Eli Lilly now sell brand products directly to cash-pay patients; our LillyDirect guide and overview of lawful GLP-1 access in 2026 cover those paths.
• Generic semaglutide. Patent timelines put a US generic years away; see our generic semaglutide timeline.

Key Takeaways

• The semaglutide shortage ended on February 21, 2025 (tirzepatide: October 2, 2024, reaffirmed December 19, 2024), and the resolutions stood.
• Bulk 503B copies ended after the 2025 wind-down periods; patient-specific 503A compounding on a documented clinical need continues and is the lawful model in 2026.
• Compounded semaglutide contains the active ingredient in Wegovy but is not itself FDA-approved as a drug.
• Salt forms (semaglutide sodium or acetate) are not the approved active ingredient, per the FDA.
• Verify the named pharmacy's state license, insist on a real prescription, and walk away from anyone claiming FDA approval or selling research peptides.